scholarly journals The Effects of Interleukin 10 and Interferon γ Cytokine Gene Polymorphisms on Survival after Autologous Bone Marrow Transplantation for Patients with Breast Cancer

2005 ◽  
Vol 11 (6) ◽  
pp. 455-464 ◽  
Author(s):  
Julie M. Wu ◽  
Debra Bensen-Kennedy ◽  
Yuji Miura ◽  
Christopher J. Thoburn ◽  
Deborah Armstrong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Gene Polymorphisms ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Interleukin 10 ◽  
Interferon Γ ◽  
Cytokine Gene ◽  
Cytokine Gene Polymorphisms ◽  
Autologous Bone

Psychologic and neuropsychologic impact of autologous bone marrow transplantation.

1996 ◽  
Vol 14 (5) ◽  
pp. 1457-1462 ◽  
Author(s):  
T A Ahles ◽  
D M Tope ◽  
C Furstenberg ◽  
D Hann ◽  
L Mills
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Cancer Patients ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Breast Cancer Patients ◽  
Hematologic Disorders ◽  
Autologous Bone ◽  
Over Time

PURPOSE The major purpose of the current study was to evaluate the psychologic and neuropsychologic functioning of patients undergoing treatment with autologous bone marrow transplantation (ABMT). PATIENTS AND METHODS Fifty-four patients with hematologic disorders or breast cancer completed a battery of psychologic and neuropsychologic tests before ABMT, at mid-treatment (1 to 3 days following bone marrow reinfusion), and predischarge (within 1 to 2 days before discharge from the hospital). RESULTS Analysis of pretransplant data showed significantly higher scores on the State-Trait Anxiety Inventory (STAI) and Profile of Mood States (POMS) for patients with hematologic disorders as compared with patients with breast cancer. However, no baseline differences on neuropsychologic measures were found when patients were divided into groups based on prior exposure to cranial radiation and/or intrathecal chemotherapy. Serial evaluations at pretransplant, following return of bone marrow, and at predischarge were available for 34 patients. For the psychologic data, patients with hematologic disorders tended to be more distressed than breast cancer patients at baseline, but became less distressed over time. By contrast, breast cancer patients were relatively less distressed at baseline, demonstrated a significant increase in distress midtreatment, and returned to baseline levels at predischarge assessment. Scores on neuropsychologic measures that assessed higher order cognitive functioning generally worsened over time. CONCLUSION The results suggest a differential response on psychologic measures when comparing patients with hematologic disorders with those with breast cancer. However, both groups demonstrated a general decline in performance on neuropsychologic measures over the course of treatment.

Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.

1994 ◽  
Vol 12 (2) ◽  
pp. 342-346 ◽  
Author(s):  
R Ghalie ◽  
C M Richman ◽  
S S Adler ◽  
M A Cobleigh ◽  
A D Korenblit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Metastatic Breast Cancer ◽  
Autologous Bone Marrow Transplantation ◽  
Metastatic Breast ◽  
Autologous Bone Marrow ◽  
Complete Response ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Autologous Bone

PURPOSE We investigated the role of high-dose chemotherapy and autologous bone marrow transplantation (ABMT) as the initial systemic treatment in patients with hormone-unresponsive metastatic breast cancer. We studied a regimen involving a split-course schedule using sequential administration of two pairs of alkylating agents separated by 5 days of rest. The rest period was intended to provide time for recovery from the treatment-immediate adverse effects, thereby allowing further dose escalation. PATIENTS AND METHODS The treatment consisted of thiotepa 225 to 300 mg/m2/d (days - 11 to -9), cisplatin 50 to 100 mg/m2/d (days - 11 and -3), and cyclophosphamide 60 mg/kg/d (days - 3 and -2). Dose escalation was performed in the initial 15 patients before reaching dose-limiting toxicities. When feasible, responding patients received posttransplant irradiation to sites of residual or prior bulky disease. Patients with bone marrow or CNS involvement, prior pelvic irradiation, or age greater than 55 years were excluded. RESULTS Thirty-nine patients with measurable or assessable tumor were enrolled: 23 with visceral metastases, 11 with only soft tissue disease, and five with skeletal involvement. Twenty-five patients had received no chemotherapy for metastatic disease before transplantation. The dose-limiting toxicities of this therapy were renal and gastrointestinal. Six patients died from complications: four of a fungal infection and two of hemorrhage. A complete response was achieved in 14 patients (36%), three of whom are free of disease at 79+, 55+, and 40+ months after transplantation. Ten of 25 patients not treated with standard-dose chemotherapy for metastatic disease achieved a complete response (40%). The three patients in continuous remission were in the untreated relapse group. CONCLUSION This single high-dose treatment achieved a relatively high complete response rate in patients with metastatic breast cancer and may have cured some of them. On the other hand, the split-course dose schedule as tested here did not permit significant dose-intensification.

Sign in / Sign up

Export Citation Format

Share Document